bluebird bio, Inc. (NASDAQ:BLUE) insider Nick Leschly sold 25,667 shares of the company’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $115.18, for a total value of $2,956,325.06. Following the sale, the insider now owns 339,368 shares of the company’s stock, valued at $39,088,406.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Nick Leschly also recently made the following trade(s):

  • On Tuesday, June 27th, Nick Leschly sold 25,000 shares of bluebird bio stock. The stock was sold at an average price of $108.05, for a total value of $2,701,250.00.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 5.090% on Friday, reaching $131.205. The company had a trading volume of 2,117,108 shares. The company has a 50-day moving average price of $97.31 and a 200-day moving average price of $92.81. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $133.10. The firm’s market capitalization is $5.98 billion.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. The business had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.59) earnings per share. Equities research analysts forecast that bluebird bio, Inc. will post ($6.82) EPS for the current fiscal year.

WARNING: This news story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/01/bluebird-bio-inc-blue-insider-nick-leschly-sells-25667-shares-of-stock.html.

A number of large investors have recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. increased its stake in bluebird bio by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after buying an additional 27 shares during the period. Teacher Retirement System of Texas increased its stake in bluebird bio by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after buying an additional 53 shares during the period. Martingale Asset Management L P increased its stake in bluebird bio by 0.6% in the first quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 100 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in bluebird bio by 0.8% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after buying an additional 140 shares during the period. Finally, Prudential Financial Inc. increased its stake in bluebird bio by 4.0% in the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after buying an additional 150 shares during the period.

Several brokerages have commented on BLUE. Wedbush restated an “outperform” rating and set a $135.00 price target (up from $121.00) on shares of bluebird bio in a research note on Friday. Cowen and Company restated an “outperform” rating on shares of bluebird bio in a research note on Thursday. Evercore ISI began coverage on bluebird bio in a research note on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price target for the company. Jefferies Group LLC restated a “buy” rating and set a $88.00 price target on shares of bluebird bio in a research note on Friday, August 11th. Finally, Morgan Stanley restated a “hold” rating on shares of bluebird bio in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $102.68.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.